01838nas a2200325   4500000000100000008004100001260001700042653003400059653001800093653001900111653001800130653001900148653001800167653002400185653003600209653003400245653003100279653002100310653001100331653001200342653002500354100001500379700001300394700001500407245011500422300000900537490000700546520094500553022001401498       1989                            d  c1989 Jan-Feb10aComplement Activating Enzymes10aComplement C110aComplement C1q10aComplement C310aComplement C3d10aComplement C410aComplement Factor B10aComplement Pathway, Alternative10aComplement Pathway, Classical10aComplement System Proteins10aErythema Nodosum10aHumans10aleprosy10aLeprosy, lepromatous1 aSehgal V N1 aSharma V1 aSharma V K00aComprehensive evaluation of complement components in the course of type I (Lepra) and type II (ENL) reactions.  a32-50 v283 a<p>Complement components C1q and C4 of classic pathway; C3d, a breakdown product of C3, and factor B of alternate pathway: and C3, a component both of classic and alternate pathways, were studied in 35 patients, comprising 18 type I (Lepra) and 17 type II (ENL) reactions. There was a significant decrease in C3 and factor B with a concomitant rise of C3d during ENL. These changes indicate their preeminent role in immunogenesis of type II (ENL) reaction. The changes in the classic pathway components, on the other hand, were insignificant, apparently suggesting its limited involvement in ENL. Furthermore, reversion of factor B and C3d after subsidence of reaction is intriguing and may indicate that they are not substantially affected even with contemporary treatment. Complement components, of both classic and alternate pathways, showed no significant alterations either during type I (Lepra) reaction or after its amelioration.</p>  a0011-9059